Shots:
- The US FDA has granted FTD to DYNE-101 for treating myotonic dystrophy type 1 (DM1). US Accelerated Approval is anticipated to submit in H1’26
- DYNE-101 is being tested in the global P-I/II ACHIEVE trial for DM1
- DYNE-101 is an antisense oligonucleotide (ASO) linked to an antibody fragment (Fab) that targets the transferrin receptor 1 (TfR1) on muscle cells
Ref: Dyne Therapeutics | Image: Dyne Therapeutics
Related News:- China’s NMPA Accepts NDA for Akeso’s Gumokimab to Treat Moderate to Severe Psoriasis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
